Saturday 6 February 2016

Global Benign Prostatic Hyperplasia Market Overview Product Pipeline Review 2015 - Acute Market Reports

'BENIGN PROSTATIC HYPERPLASIA - Product Pipeline Review - 2015', provides an overview of the BENIGN PROSTATIC HYPERPLASIA's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of BENIGN PROSTATIC HYPERPLASIA's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

View Full Reporthttp://www.acutemarketreports.com/report/benign-prostatic-hyperplasia-pipeline-review-h1-2015

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of BENIGN PROSTATIC HYPERPLASIA including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of BENIGN PROSTATIC HYPERPLASIA's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the BENIGN PROSTATIC HYPERPLASIA's pipeline products

Reasons to buy

- Evaluate BENIGN PROSTATIC HYPERPLASIA's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of BENIGN PROSTATIC HYPERPLASIA in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the BENIGN PROSTATIC HYPERPLASIA's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of BENIGN PROSTATIC HYPERPLASIA and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of BENIGN PROSTATIC HYPERPLASIA
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of BENIGN PROSTATIC HYPERPLASIA and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

About Us:
Acute Market Reports is the most sufficient collection of market intelligence services online. It is your only source that can fulfill all your market research requirements. We provide online reports from over 100 best publishers and upgrade our collection regularly to offer you direct online access to the world’s most comprehensive and recent database with expert perceptions on worldwide industries, products, establishments and trends. Our database consists of 200,000+ market research reports with detailed & minute market research.
Acute Market Reports
Office No 101, 1st Floor,
Aditi Mall, Baner,
Pune, MH, 411045
India
Toll Free(US/CANADA): +1-855-455-8662

Global AvidBiotics Corp. Market Information Management Report Product Pipeline Review 2015 - Acute Market Reports

'AVIDBIOTICS CORP. - Product Pipeline Review - 2015', provides an overview of the AVIDBIOTICS CORP.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of AVIDBIOTICS CORP.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

View Full Reporthttp://www.acutemarketreports.com/report/avidbiotics-corp-product-pipeline-review-2015

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of AVIDBIOTICS CORP. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of AVIDBIOTICS CORP.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the AVIDBIOTICS CORP.'s pipeline products

Reasons to buy

- Evaluate AVIDBIOTICS CORP.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of AVIDBIOTICS CORP. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the AVIDBIOTICS CORP.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of AVIDBIOTICS CORP. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of AVIDBIOTICS CORP.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of AVIDBIOTICS CORP. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

About Us:
Acute Market Reports is the most sufficient collection of market intelligence services online. It is your only source that can fulfill all your market research requirements. We provide online reports from over 100 best publishers and upgrade our collection regularly to offer you direct online access to the world’s most comprehensive and recent database with expert perceptions on worldwide industries, products, establishments and trends. Our database consists of 200,000+ market research reports with detailed & minute market research.
Acute Market Reports
Office No 101, 1st Floor,
Aditi Mall, Baner,
Pune, MH, 411045
India
Toll Free(US/CANADA): +1-855-455-8662

Global Ankylosing Spondylitis (Bekhterev's Disease) Market Overview Product Pipeline Review 2015 - Acute Market Reports

'ANKYLOSING SPONDYLITIS (BEKHTEREV’S DISEASE) - Product Pipeline Review - 2015', provides an overview of the ANKYLOSING SPONDYLITIS (BEKHTEREV’S DISEASE)'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of ANKYLOSING SPONDYLITIS (BEKHTEREV’S DISEASE)'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

View Full Reporthttp://www.acutemarketreports.com/report/ankylosing-spondylitis-bekhterevs-disease-pipeline-review-h1-2015

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of ANKYLOSING SPONDYLITIS (BEKHTEREV’S DISEASE) including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of ANKYLOSING SPONDYLITIS (BEKHTEREV’S DISEASE)'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the ANKYLOSING SPONDYLITIS (BEKHTEREV’S DISEASE)'s pipeline products

Reasons to buy

- Evaluate ANKYLOSING SPONDYLITIS (BEKHTEREV’S DISEASE)'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of ANKYLOSING SPONDYLITIS (BEKHTEREV’S DISEASE) in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the ANKYLOSING SPONDYLITIS (BEKHTEREV’S DISEASE)'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of ANKYLOSING SPONDYLITIS (BEKHTEREV’S DISEASE) and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of ANKYLOSING SPONDYLITIS (BEKHTEREV’S DISEASE)
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of ANKYLOSING SPONDYLITIS (BEKHTEREV’S DISEASE) and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

About Us:
Acute Market Reports is the most sufficient collection of market intelligence services online. It is your only source that can fulfill all your market research requirements. We provide online reports from over 100 best publishers and upgrade our collection regularly to offer you direct online access to the world’s most comprehensive and recent database with expert perceptions on worldwide industries, products, establishments and trends. Our database consists of 200,000+ market research reports with detailed & minute market research.
Acute Market Reports
Office No 101, 1st Floor,
Aditi Mall, Baner,
Pune, MH, 411045
India
Toll Free(US/CANADA): +1-855-455-8662

Global Adenocarcinoma Of The Gastroesophageal Junction Market Segmentation and Forecast Product Pipeline Review 2015 - Acute Market Reports

'ADENOCARCINOMA OF THE GASTROESOPHAGEAL JUNCTION - Product Pipeline Review - 2015', provides an overview of the ADENOCARCINOMA OF THE GASTROESOPHAGEAL JUNCTION's pharmaceutical research and development focus.
This report provides comprehensive information on the current therapeutic developmental pipeline of ADENOCARCINOMA OF THE GASTROESOPHAGEAL JUNCTION's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.
Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Download Full Report With TOChttp://www.acutemarketreports.com/request-free-sample/49744
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides brief overview of ADENOCARCINOMA OF THE GASTROESOPHAGEAL JUNCTION including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of ADENOCARCINOMA OF THE GASTROESOPHAGEAL JUNCTION's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the ADENOCARCINOMA OF THE GASTROESOPHAGEAL JUNCTION's pipeline products
View all Reports of this Category @: http://www.acutemarketreports.com/category/healthcare-market
Reasons to buy
- Evaluate ADENOCARCINOMA OF THE GASTROESOPHAGEAL JUNCTION's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of ADENOCARCINOMA OF THE GASTROESOPHAGEAL JUNCTION in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the ADENOCARCINOMA OF THE GASTROESOPHAGEAL JUNCTION's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of ADENOCARCINOMA OF THE GASTROESOPHAGEAL JUNCTION and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of ADENOCARCINOMA OF THE GASTROESOPHAGEAL JUNCTION
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of ADENOCARCINOMA OF THE GASTROESOPHAGEAL JUNCTION and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
About Us:
Acute Market Reports is the most sufficient collection of market intelligence services online. It is your only source that can fulfill all your market research requirements. We provide online reports from over 100 best publishers and upgrade our collection regularly to offer you direct online access to the world’s most comprehensive and recent database with expert perceptions on worldwide industries, products, establishments and trends. Our database consists of 200,000+ market research reports with detailed & minute market research.
Acute Market Reports
Office No 101, 1st Floor,
Aditi Mall, Baner,
Pune, MH, 411045
India
Toll Free(US/CANADA): +1-855-455-8662

Friday 5 February 2016

New Study On Global CymaBay Therapeutics, Inc. Market Report Product Pipeline Review 2015 - Acute Market Reports

'CYMABAY THERAPEUTICS, INC. - Product Pipeline Review - 2015', provides an overview of the CYMABAY THERAPEUTICS, INC.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of CYMABAY THERAPEUTICS, INC.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

View Full Reporthttp://www.acutemarketreports.com/report/cymabay-therapeutics-inc-product-pipeline-review-2015

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of CYMABAY THERAPEUTICS, INC. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of CYMABAY THERAPEUTICS, INC.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the CYMABAY THERAPEUTICS, INC.'s pipeline products

Reasons to buy

- Evaluate CYMABAY THERAPEUTICS, INC.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of CYMABAY THERAPEUTICS, INC. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the CYMABAY THERAPEUTICS, INC.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of CYMABAY THERAPEUTICS, INC. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of CYMABAY THERAPEUTICS, INC.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of CYMABAY THERAPEUTICS, INC. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

About Us:
Acute Market Reports is the most sufficient collection of market intelligence services online. It is your only source that can fulfill all your market research requirements. We provide online reports from over 100 best publishers and upgrade our collection regularly to offer you direct online access to the world’s most comprehensive and recent database with expert perceptions on worldwide industries, products, establishments and trends. Our database consists of 200,000+ market research reports with detailed & minute market research.
Acute Market Reports
Office No 101, 1st Floor,
Aditi Mall, Baner,
Pune, MH, 411045
India
Toll Free(US/CANADA): +1-855-455-8662

Recent Release On Global CYATHUS EXQUIRERE PharmaforschungsGmbH Market Report Product Pipeline Review 2015 - Acute Market Reports

'CYATHUS EXQUIRERE PHARMAFORSCHUNGSGMBH - Product Pipeline Review - 2015', provides an overview of the CYATHUS EXQUIRERE PHARMAFORSCHUNGSGMBH's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of CYATHUS EXQUIRERE PHARMAFORSCHUNGSGMBH's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

View Full Reporthttp://www.acutemarketreports.com/report/cyathus-exquirere-pharmaforschungsgmbh-product-pipeline-review-2015

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of CYATHUS EXQUIRERE PHARMAFORSCHUNGSGMBH including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of CYATHUS EXQUIRERE PHARMAFORSCHUNGSGMBH's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the CYATHUS EXQUIRERE PHARMAFORSCHUNGSGMBH's pipeline products

Reasons to buy

- Evaluate CYATHUS EXQUIRERE PHARMAFORSCHUNGSGMBH's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of CYATHUS EXQUIRERE PHARMAFORSCHUNGSGMBH in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the CYATHUS EXQUIRERE PHARMAFORSCHUNGSGMBH's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of CYATHUS EXQUIRERE PHARMAFORSCHUNGSGMBH and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of CYATHUS EXQUIRERE PHARMAFORSCHUNGSGMBH
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of CYATHUS EXQUIRERE PHARMAFORSCHUNGSGMBH and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

About Us:
Acute Market Reports is the most sufficient collection of market intelligence services online. It is your only source that can fulfill all your market research requirements. We provide online reports from over 100 best publishers and upgrade our collection regularly to offer you direct online access to the world’s most comprehensive and recent database with expert perceptions on worldwide industries, products, establishments and trends. Our database consists of 200,000+ market research reports with detailed & minute market research.
Acute Market Reports
Office No 101, 1st Floor,
Aditi Mall, Baner,
Pune, MH, 411045
India
Toll Free(US/CANADA): +1-855-455-8662

Latest Global Curis, Inc. Market Research Report Product Pipeline Review 2015 - Acute Market Reports

'CURIS, INC. - Product Pipeline Review - 2015', provides an overview of the CURIS, INC.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of CURIS, INC.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

View Full Reporthttp://www.acutemarketreports.com/report/curis-inc-product-pipeline-review-2015

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of CURIS, INC. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of CURIS, INC.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the CURIS, INC.'s pipeline products

Reasons to buy

- Evaluate CURIS, INC.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of CURIS, INC. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the CURIS, INC.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of CURIS, INC. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of CURIS, INC.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of CURIS, INC. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

About Us:
Acute Market Reports is the most sufficient collection of market intelligence services online. It is your only source that can fulfill all your market research requirements. We provide online reports from over 100 best publishers and upgrade our collection regularly to offer you direct online access to the world’s most comprehensive and recent database with expert perceptions on worldwide industries, products, establishments and trends. Our database consists of 200,000+ market research reports with detailed & minute market research.
Acute Market Reports
Office No 101, 1st Floor,
Aditi Mall, Baner,
Pune, MH, 411045
India
Toll Free(US/CANADA): +1-855-455-8662